established in late 1999 scientific/clinical resources ethics committees regulatory body
DESCRIPTION
Established in late 1999 Scientific/clinical resources Ethics committees Regulatory body. TT - 2002. SAAVI aims to develop an affordable , effective and locally relevant preventative HIV vaccine for southern Africa. G. G. J. J. AE. G. AE. H. AE. AG. AG. B. B. B. AG. B. B. - PowerPoint PPT PresentationTRANSCRIPT
Established in late 1999
• Scientific/clinical resources
• Ethics committees
• Regulatory bodyTT - 2002
SAAVI aims to develop an affordable, effective and locally relevant preventative HIV vaccine for southern
Africa
HIV genetic diversityHIV genetic diversity
CC CC CC
CCCC
AA AAAA AAAGAGAGAG AGAG
AEAEAEAE AEAE
GGGG GG JJJJ
HHBB
BB BB BBBBBB
BBDDDD
DDDD
DD
FFFFKK
KK
CCCCCCCC
CCCC
CCCC
CCCC
CC
CC
C. Williamson et al
Making the vaccine
Testing the vaccine
Ethicalissues
Advocacy& community
Others
TT - 2002
Immunologyassessment
Human Animal
What do we expect from What do we expect from an HIV vaccine?an HIV vaccine?
““Viral load” in HIVViral load” in HIV
Am
o un t
of H
I V
5%
90%
Progress toAIDS in 5 years
Potential end-points of HIV-Potential end-points of HIV-vaccine efficacy trialsvaccine efficacy trials
TT - 2002
SAAVI ChallengesSAAVI Challenges
Making the vaccine
Testing the vaccine
Ethicalissues
Advocacy& community
Others
TT - 2002
Immunologyassessment
Human Animal
TT - 2002
Supporters and Funds
Source TOTAL 2001 TOTAL 2002Department of Health R 5,000,000 R 10,000,000Department of Arts, Culture, Science and TechnologyR 10,000,000 R 10,000,000Eskom R 7,500,000 R 15,000,000HIV Vaccine Trial Network R 7,000,000 R 8,000,000NIH Vaccine Development Research Committee (VDRG) R 0 R 18,000,000European Union R 5,000,000 R 5,000,000Corporation A R 10,000,000
TOTAL R 34,500,000 R 76,000,000
TT - 2002
1. Good vaccine candidates
2. HIV subtypes
3. Community involvement
4. Ethical studies
5. Access to product
6. Pricing
7. Technology transfer
Appropriate Clinical Trials
$30
mill
ion
TT - 2002
Manufacturing 1. Product?
2. When?
3. What dose?
4. Manufacturing plant
5. Personnel
6. Dose price
7. Distribution capacity
$350
milli
on
•Clinical trials lot
•Bulk supply
TT - 2002
1. Government
2. Medicines Control Council
3. Ethics committees
4. Medical aids
5. Life Insurance
6. Blood transfusion services
7. State Vaccine Institute
Strategic nationalalliances
TT - 2002
Strategic international alliances
1. NIH
2. HVTN
3. IAVI
4. AAVP
5. EU
6. Public / private
CONCLUSIONSCONCLUSIONS
• SAAVI has dynamic team
• Different to all other initiatives
• Committed to excellence
• Massive / maturing challenges
• Consolidate and expand
TT - 2002